News

AXIM Biotechnologies, Inc. (AXIM)’s clinical trials testing a new pharmaceutical-grade cannabis chewing gum treatment option for Multiple Sclerosis (MS) pain and spasticity are drawing lots of popular and specialty media attention, with reports in Multiple Sclerosis News Today, Marketwatch, Yahoo! Finance, Wall Street Journal, CNN Money,…

Pharmaceutical giant Novartis recently announced it has signed an agreement with GlaxoSmithKline for exclusive rights to GSK’s investigational CD20-specific monoclonal antibody, Ofatumumab, indicated for relapsing remitting multiple sclerosis (RRMS) and other autoimmune diseases. Novartis had previously acquired rights to the drug for its indications in oncology, effectively marketing it under brand name Arzerra®.

Omnicare, a Fortune 500 company based in Cincinnati, Ohio that provides comprehensive pharmaceutical services to patients and providers across the United States, recently made a generous donation of $100,000 to the National Multiple Sclerosis Society’s inaugural No Opportunity Wasted (NOW) campaign. The NOW campaign aims to raise $250 million to help boost ongoing research…

A recently published study in the journal Neurology entitled “lower physical activity is associated with higher disease burden in pediatric multiple sclerosis” suggests pediatric patients with multiple sclerosis can benefit from engaging in regular moderate to strenuous activity, in that physical activity was linked to a…

In a new review entitled “Fatigue in multiple sclerosis: a look at the role of poor sleep” author Lauren Strober, PhD explores the link between secondary fatigue and sleep disturbance in multiple sclerosis patients. The study was published in the journal Frontiers in Neurology.

A survey of 97 neurologists conducted in June 2015 revealed specialists within the field of neurology are increasingly avoiding prescribing injectables to patients suffering from multiple sclerosis, as orally-available disease modifying-agents (DMAs) continue to gain in popularity. The survey was conducted and reported by Spherix Global Insights, a newly established business…

Every year, the National Multiple Sclerosis Society hosts MuckFest MS, a fun mud and obstacle 5K event that raises funds for the society’s mission to support the ongoing search for better treatments and solutions for multiple sclerosis. Earlier this week, the Society gave recognition to the event’s 100,000 “mucker” or…

AXIM Biotechnologies, Inc., a biotechnology company focused on global research, development and production of pharmaceutical, nutraceutical, food and cosmetic products derived from industrial hemp, has announced commencement of clinical development of its leading patented pharmaceutical chewing gum, MedChew RX, for registration as a drug for relieving pain and/or spasticity…

Clinical stage biotech company Vitae Pharmaceuticals, Inc., recently announced the launch of a Phase I multiple ascending dose clinical study of VTP-43742, the company’s first-in-class RORγt inhibitor pipeline drug, indicated for the treatment of autoimmune diseases such as multiple sclerosis (MS) and several other orphan indications. Preclinical studies of VTP-43742 exhibited the…

Apitope, a biocompany devoted to drug discovery and development for autoimmune diseases, announced that its partner Merck Serono has concluded the recruitment of participants for its Phase IIa Trial on relapsing multiple sclerosis, (known as a Phase IIa study of ATX-MS-1467 or also M2736) The drug, ATX-MS-1467, is an…

A recent research study focused on whether regular exercise can benefit children with multiple sclerosis (MS). The article appeared in the August 12, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. MS is characterized by inflammation, which manifests as an…

The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation (MSSRF) have announced the awarding of a $3.2 million grant in support of the Canadian Pediatric Demyelinating Disease Network. Canada has the highest rate of multiple sclerosis (MS) in the world, and is one of the…

A new study published in the journal Statistical Methods in Medical Research revealed a new method to determine the disease course in multiple sclerosis (MS) patients. The study is entitled “Joint assessment of dependent discrete disease state processes” and was conducted by researchers at…

Most people know that eating too much salt is bad for your health, but a new study suggests that it could also increase the risk for multiple sclerosis (MS). The work appeared in the August 2015 issue of The FASEB Journal, the journal of the Federation of…

Multiple sclerosis patients prescribed Gilenya (fingolimod) are now being informed about a handful of documented cases where the therapy was found to have led to a rare brain infection, according to the US Food and Drug Administration. The FDA has released a public warning indicating that cases of progressive multifocal leukoencephalopathy (PML) have been…

Netherlands-based international pharmaceutical company Synthon, best known for developing complex generic therapeutics, has officially entered into an agreement with pharmaceutical giant Pfizer, Inc., effectively transferring the exclusive rights in the US to glatiramer acetate to Pfizer. Glatiramer acetate is an experimental generic formulation of Copaxone, which is indicated as a…

The non-profit organization MS News and Views (MSVN) announced that it will host four educational events during the month of August for both patients and other people interested in learning more about multiple sclerosis (MS). The educational events reflect the organization’s ongoing mission, which is to collect, present and…

A new study testing Amarantus Diagnostics’ MSPrecise on multiple sclerosis patients identified the test as a specific and sensitive diagnostic test for multiple sclerosis. The test accurately diagnosed 84% of multiple sclerosis patients from a broad range of subjects with potential neurological diseases. These results further support Amarantus Diagnostics’ ability to design next generation…

In a new study entitled “Polymorphonuclear Cell Functional Impairment in Relapsing Remitting Multiple Sclerosis Patients: Preliminary Data” researchers investigated how polymorphonuclear cells — important players of the innate immune system — are altered in multiple sclerosis patients. The study was published in the journal PLOS…

An Open Access research article published in the journal BMC Medical Genetics notes that multiple sclerosis (MS) has a strong genetic component, observing high MS prevalence in European populations including those of Ashkenazi Jewish origin, and low in African and Asian populations also including those of…

The major challenge patients with multiple sclerosis face is nearly constant muscle weakness and fatigue caused by progressive nerve and neurological damage. It is well established that these symptoms dramatically affect quality of life in MS patients, making it more difficult to work, partake in hobbies, and enjoy family and social interactions.

Cambridge, Massachusetts based Biogen Inc. has reported its second quarter 2015 results, posting a year-over-year seven percent revenue increase to $2.6 Billion in the quarter. “Biogen remains focused on improving the lives of people living with complex diseases,” says Chief Executive Officer George A. Scangos, Ph.D. “Tecfidera, which is now…

Progressive multiple sclerosis patients treated with AB Science’s lead compound AB07002 (masitinib) in a Phase 3 clinical trial showed positive results in a non futility test (a test to determine if an experimental therapy shows some sign of efficacy). With the successful completion of the futility analysis, AB Science is…

Personalized medicine, often applied to treat cancer, may be possible for patients with multiple sclerosis as well. Certain patients respond differently to certain multiple sclerosis medications, such as interferon-β (IFNβ), and researchers at San Raffaele Scientific Institute in Milan may have an answer as to why. The team, led by…

Relapsing remitting multiple sclerosis (RRMS) treatment Plegridy (peg interferon beta-1a) by Biogen Idec, has just received Welsh NHS approval, which should make it available to patients by late October 2015. The decision follows NHS Scotland’s approval earlier this year, however, the biweekly interferon beta shot has yet to be made available in England’s NICE…

Multiple sclerosis (MS) is a devastating, progressive disease of the nervous system. It is caused by loss of myelin, a fatty substance that wraps around nerve cells and allows them to conduct impulses and communicate. When myelin is lost, areas of damage called “lesions” result, which appear in the brain and…

Nutra Pharma, a US-based biotechnology a company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, recently announced that it has filed an application with the US Food and Drug Administration (FDA) for orphan drug status…

Fingolimod, also known by its brand name Gilenya, is an oral immunotherapy approved for the treatment of relapsing-remitting multiple sclerosis (MS). In a recent study published in the Journal PLOS One, a team of researchers found that the autonomic cardiovascular dysfunction in MS patients with delayed heart ratere-acceleration…

A study recently published in the journal PLoS One revealed an excess mortality rate among French patients with multiple sclerosis (MS) that experience the disease for more than 20 years. The study was conducted by researchers at several institutes and hospitals in France, and is entitled “…

Summit, New Jersey based Celgene Corporation and Receptos, Inc. of San Diego, California, a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, have announced their joint signing of a definitive agreement in which Celgene will acquire Receptos. Under terms of the merger agreement,…